Study: Teplizumab may delay type 1 diabetes progression

06/29/2011 | WebMD

Patients treated with the experimental diabetes drug teplizumab had better beta cell preservation than those given a placebo, experts reported at the annual meeting of the American Diabetes Association and online in The Lancet. Though it did not meet target glucose levels, teplizumab appears to delay the progression of type 1 diabetes in patients, researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA